Clinical Trials Logo
  1. Home
  2. Methamphetamine Use Disorder
  3. NCT03078075

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder — ADAPT-2  

Methamphetamine Use Disorder Clinical Trial

Official title:
NIDA (National Institute on Drug Abuse) CTN (Clinical Trials Network) Protocol 0068: Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

Clinical Trial Summary

This is a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. Participants will be randomly assigned to the active medication combination (AMC) group or matching placebo group and will receive medications over the course of 12 weeks. Follow-ups will occur in weeks 13 and 16.

Clinical Trial Description

There will be 400 adults with moderate or severe methamphetamine use disorder randomized into this multi-site study. Eligibility will be determined during a maximum 21 day screening period. After screening is completed and eligibility is confirmed, including successful administration of a naloxone challenge, participants will begin the 12 week medication phase of the trial. Participants will be randomized to either the 1) AMC arm and receive injections of extended release naltrexone (XR-NTX; as Vivitrol®) plus once-daily oral extended-release bupropion tablets (BUP-XL) or the 2) matching placebo (PLB) arm and receive injections of placebo (iPLB) plus once-daily oral placebo (oPLB) tablets. During the course of the study, participants may be switched to another arm, as determined by the a priori adaptive aspect of the study design. Participants appearing to respond well to their original treatment assignment will not be switched. Overall, approximately 50% of the participants will receive the AMC. Injections will be administered every three weeks, in weeks 1, 4, 7, and 10. Take-home oral study medication (BUP-XL or oPLB) will be dispensed weekly for dosing on non-clinic days. Participants will be asked to attend the clinic twice weekly for observed oral medication dosing, assessments, collection of urine samples, and once-weekly medical management. On non-clinic days, participants will participate in smartphone app-based medication adherence activities. Participants will be asked to complete assessments as indicated on the schedule of assessments. Following the 12 week medication phase, participants will complete a follow-up phase, including a medication taper and post-medication phase follow-up visits during weeks 13 and 16. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03078075
Study type Interventional
Source University of Texas Southwestern Medical Center
Contact
Status Completed
Phase Phase 3
Start date May 5, 2017
Completion date July 25, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT04178993 - Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine] Phase 1
Completed NCT01982643 - Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder Phase 1/Phase 2
Terminated NCT05711862 - The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder Phase 2
Recruiting NCT05322954 - Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder Phase 1
Recruiting NCT05760807 - Intranasal Oxytocin for Methamphetamine Withdrawal in Women N/A
Recruiting NCT04614584 - Mirtazapine and Methamphetamine Drug-drug Interaction Study Phase 1
Not yet recruiting NCT06320366 - Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder N/A
Recruiting NCT05558358 - Deep Brain Stimulation (DBS) for Methamphetamine Use Disorder Phase 1/Phase 2
Active, not recruiting NCT06279273 - A Study for the Risky Decision-making Deficits Among Methamphetamine Dependence Individuals and Treatment N/A
Active, not recruiting NCT04907357 - rTMS for Stimulant Use Disorders N/A
Completed NCT04713124 - A Telephone-delievered Intervention to Reduce Methamphetamine Use N/A
Active, not recruiting NCT04791969 - Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM Phase 2
Completed NCT00572234 - Bupropion in the Treatment of Methamphetamine Dependence N/A
Terminated NCT03106571 - Study of Pomaglumetad and Methamphetamine Phase 1
Recruiting NCT06033365 - Beginning Early and Assertive Treatment for Methamphetamine Use Disorder N/A